ArticleBMC neurology2026
Sleep disorders in patients with myasthenia gravis based on antibody subtypes: a polysomnographic study.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSleep-disordered breathing (SDB) is increasingly recognized in myasthenia gravis (MG), yet potential differences in sleep respiratory patterns between antibody-defined MG subtypes remain poorly understood. We aimed to evaluate sleep disorders and polysomnographic characteristics in patients with acetylcholine receptor antibody–positive (AChR-MG) and muscle-specific tyrosine kinase antibody–positive (MuSK-MG) generalized MG.
methodsEighteen clinically stable MG patients (9 AChR-MG, 9 MuSK-MG) and 9 healthy controls underwent attended overnight polysomnography followed by the Multiple Sleep Latency Test (MSLT). Standardized sleep questionnaires and MG clinical scales were administered to assess sleep-related symptoms and disease severity.
resultsObstructive sleep apnea was detected in 89% of AChR-MG and 78% of MuSK-MG patients. Both MG subgroups showed significantly higher apnea–hypopnea index values compared with controls (p < 0.05). Although overall AHI severity did not differ significantly between antibody groups, distinct respiratory patterns were observed. Respiratory events clustered predominantly during REM sleep in AChR-MG, whereas MuSK-MG patients exhibited more frequent events during NREM or supine sleep.
conclusionsSleep-disordered breathing appears to be common in MG, but polysomnographic patterns may differ according to antibody subtype. REM-predominant respiratory events in AChR-MG and NREM or positional predominance in MuSK-MG may reflect differences in muscle involvement between these subtypes. These findings suggest that antibody-specific mechanisms may influence nocturnal respiratory dysfunction in MG and highlight the importance of targeted sleep assessment in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.